'One injection protects up to six months': what is new HIV drug lenacapavir?
Lenacapavir is a new long-acting HIV treatment requiring only two injections annually, offering an alternative to daily pills by preventing HIV virus assembly. While promising, concerns remain regarding its cost, accessibility, and sufficient supply, especially in countries like South Africa and Cameroon with high HIV populations.
Why it matters
This new treatment could significantly improve adherence and quality of life for people living with HIV, but equitable global access and affordability are crucial challenges that need to be addressed to maximize its public health impact.
New long-acting antiretroviral treatment lenacapavir requires just two injections a year, reducing the need for daily pills. But questions remain over access, cost and whether enough doses will be available to meet demand in the country with the world's largest HIV-positive population.
The article presents factual information about a new medical treatment, discussing its benefits and challenges in a balanced, scientific manner.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in